Michael Albin, Ph.D., Appointed Vice President, Strategic ...

Michael Albin, Ph.D., Appointed Vice President, Strategic Technologies for Applera Corporation NORWALK, Conn.--(BW HealthWire)--Nov. 8, 2001--Applera Corporation today announced that Michael Albin, Ph.D., has been appointed Vice President, Strategic Technologies. Dr. Albin will report to Tony L. White, Applera Chairman and Chief Executive Officer, and will be a member of the corporation's Executive Committee. In this new position, he will play an independent role in assessing technology opportunities affecting more than one of Applera's three business units - Applied Biosystems Group (NYSE:ABI), Celera Genomics Group (NYSE:CRA) and Celera Diagnostics, a joint venture between Applied Biosystems and Celera Genomics. Dr. Albin joined Applied Biosystems as a senior scientist in 1989, and was appointed Vice President, Science and Technology for Applied Biosystems in 1998. He was responsible for technology assessment and early stage development, R&D planning, and was a key member of the Applied Biosystems business development team. He earned his bachelor's degree in chemistry in 1979 from Polytechnic Institute, Brooklyn, NY and his Ph.D. in chemistry in 1984 from Pennsylvania State University. He completed his postdoctoral studies in biology at the California Institute of Technology. Dr. Albin also serves on the industrial advisory boards of Penn State and the University of California, San Diego. "In his new position, Mike will work with the heads of our businesses and their staffs to understand the strategic direction of each business unit, and provide appropriate technical direction and consultation on research programs in order to update ongoing programs and recommend possible further collaborations. He will also provide guidance on the corporation's strategic technical direction and focus," Mr. White said. "Mike's appointment to this new position recognizes his long and valuable service to Applied Biosystems, and his broad-based understanding of the technologies important to the future of all three Applera organizations." About Applera Corporation and Applied Biosystems Applera Corporation comprises two operating groups. The Applied Biosystems Group develops and markets instrument-based systems, reagents, software, and contract services to the life science industry and research community. Customers use these tools to analyze nucleic acids (DNA and RNA), small molecules, and proteins to make scientific discoveries, leading to the development of new pharmaceuticals, and to conduct standardized testing. Applied Biosystems is headquartered in Foster City, CA, and reported sales of $1.6 billion during fiscal 2001. The Celera Genomics Group, an integrated source of genomic and related medical information headquartered in Rockville, MD, is evolving to become a next generation therapeutic discovery business. Celera intends to leverage its industrialized approach to biology to develop platforms for enabling these new discoveries both for its own internal product development and for its customers, including collaboration partners and subscribers. Celera Diagnostics has been established as a joint venture between Applied Biosystems and Celera Genomics. This new venture is focused on discovery, development and commercialization of novel diagnostic tests. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available on the World Wide Web at www.applera.com, or by telephoning 800.762.6923. Information about Applied Biosystems is available on the World Wide Web at www.appliedbiosystems.com. CONTACT: Applied Biosystems Media Lori Murray 650/638-6130 [email protected] Investors Applied Biosystems Peter Dworkin 650/554-2479 [email protected]